2018
Long-term outcomes of mitral regurgitation by type and severity
Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, Alexander JH, Kisslo JA, Wang A, Mark DB, Velazquez EJ. Long-term outcomes of mitral regurgitation by type and severity. American Heart Journal 2018, 203: 39-48. PMID: 30015067, DOI: 10.1016/j.ahj.2018.05.001.Peer-Reviewed Original ResearchConceptsMR severityCause deathIschemic MRSurvival rateCause death riskCoronary artery diseaseLong-term outcomesAbsolute mortality ratesQualifying patientsArtery diseaseEchocardiography studyMitral regurgitationVentricular sizeIndeterminate causeBaseline severityDeath riskSevere MREchocardiography laboratoryHigh riskMortality rateClinical settingPatientsValve morphologySeverityMyxomatousRationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal 2018, 198: 145-151. PMID: 29653636, DOI: 10.1016/j.ahj.2018.01.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAminobutyratesBiphenyl CompoundsCardiac Output, LowCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsDrug Delivery SystemsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPatient SafetyPeptide FragmentsPrognosisProspective StudiesRisk AssessmentSeverity of Illness IndexSurvival RateTetrazolesTreatment OutcomeValsartanConceptsAcute decompensated heart failureSacubitril/valsartanB-type natriuretic peptideDecompensated heart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptideEjection fractionHeart failureHospital initiationNatriuretic peptideEnd pointClass angiotensin receptor neprilysin inhibitorAngiotensin receptor neprilysin inhibitorPg/Primary efficacy end pointAmbulatory HF patientsExploratory end pointsPIONEER-HF trialEfficacy end pointReduced ejection fractionSafety end pointOpen-label treatmentIncidence of angioedemaYears of agePIONEER-HFPrior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients. Journal Of The American Heart Association 2018, 7: e006940. PMID: 29301757, PMCID: PMC5778960, DOI: 10.1161/jaha.117.006940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCause of DeathDrug Therapy, CombinationFemaleHumansHydrochlorothiazideHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSodium Chloride Symporter InhibitorsTime FactorsTreatment OutcomeConceptsHigh-risk hypertensive patientsCardiovascular risk reductionHypertensive patientsAntihypertensive regimenCombination therapyBlood pressure control statusGreater cardiovascular risk reductionRenin-angiotensin system blockadeAngiotensin-converting enzyme inhibitorPrimary composite eventsPrior antihypertensive therapyPrimary composite outcomeCalcium channel blockadeLipid-lowering medicationsPrior medication useCalcium channel blockersRisk reductionACCOMPLISH trialAntihypertensive therapySystem blockadeCardiovascular benefitsCombination regimenComposite outcomeDrug regimensMedication use
2017
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF
Pokorney SD, Al‐Khatib S, Sun J, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF. European Journal Of Heart Failure 2017, 20: 525-532. PMID: 29266564, DOI: 10.1002/ejhf.1078.Peer-Reviewed Original ResearchConceptsSudden cardiac deathVT/VFHeart failure hospital admissionsAcute HFCardiac deathHospital admissionVentricular tachycardia/ventricular fibrillationDecompensated Heart Failure (ASCEND-HF) trialChronic obstructive pulmonary diseaseVT/VF eventsEvent ratesComposite event rateMeier event ratesHeart Failure TrialCause mortality ratesDay of admissionObstructive pulmonary diseaseLonger QRS durationCause mortalityBaseline characteristicsComposite endpointEjection fractionPulmonary diseaseASCEND-HFFailure TrialRace and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction
Randolph TC, Broderick S, Shaw LK, Chiswell K, Mentz RJ, Kutyifa V, Velazquez EJ, Gilliam FR, Thomas KL. Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. Journal Of The American Heart Association 2017, 6: e004381. PMID: 28320746, PMCID: PMC5523998, DOI: 10.1161/jaha.116.004381.Peer-Reviewed Original ResearchConceptsQRS durationBundle branch blockWhite patientsHeart failureBlack patientsBranch blockNon-left bundle branch block morphologyLeft ventricular systolic dysfunctionMultivariable Cox regression modelsBundle branch block morphologyLeft bundle branch blockMedian QRS durationVentricular systolic dysfunctionHeart failure patientsVentricular ejection fractionShorter QRS durationCox regression modelRisk of mortalityDuke University HospitalBlack individualsSex differencesCause mortalitySystolic dysfunctionCoronary angiographyEjection fractionComparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease)
Banks A, Broderick S, Chiswell K, Shaw L, Devore A, Fiuzat M, O'Connor C, Felker GM, Velazquez E, Mentz R. Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). The American Journal Of Cardiology 2017, 119: 1703-1709. PMID: 28395884, DOI: 10.1016/j.amjcard.2017.02.053.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseAngina pectorisDiabetes mellitusDM statusCause mortalityMultivariable Cox regressionOutcomes of patientsDifferent prognostic implicationsSeverity of diseaseAP statusCV hospitalizationClinical characteristicsArtery diseaseCoronary angiographyDM patientsClinical outcomesCox regressionPrognostic implicationsPrognostic utilityRevascularizationSimilar riskPatientsRisk adjustmentMortalityPectoris
2016
Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal Of Medicine 2016, 374: 1511-1520. PMID: 27040723, PMCID: PMC4938005, DOI: 10.1056/nejmoa1602001.Peer-Reviewed Original ResearchConceptsMedical therapy groupCardiovascular causesCoronary artery diseaseMedical therapyCABG groupArtery diseaseIschemic cardiomyopathySevere left ventricular systolic dysfunctionGuideline-directed medical therapyLeft ventricular systolic dysfunctionMajor secondary outcomesCoronary artery bypassPrimary outcome eventVentricular systolic dysfunctionArtery bypass surgeryCohort of patientsRate of deathSystolic dysfunctionBypass surgeryMedian durationSecondary outcomesSurvival benefitEjection fractionHeart failurePrimary outcome
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailureImportance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction Insights From STICH
Jolicœur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC, Stewart R, Jhund PS, Desvigne-Nickens P, Panza JA, Bonow RO, Sun B, San TR, Al-Khalidi HR, Rouleau JL, Velazquez EJ, Cleland JGF. Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction Insights From STICH. Journal Of The American College Of Cardiology 2015, 66: 2092-2100. PMID: 26541919, PMCID: PMC4655599, DOI: 10.1016/j.jacc.2015.08.882.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseLV systolic dysfunctionGreater survival benefitMedical therapySystolic dysfunctionCause mortalitySurvival benefitWorse prognosisCoronary artery bypass graft surgeryLeft ventricular systolic dysfunctionArtery bypass graft surgeryLong-term clinical outcomesGreater prognostic benefitBypass graft surgeryVentricular systolic dysfunctionEffect of CABGMultivariable CoxSTICH trialGraft surgeryPrognostic benefitArtery diseaseCoronary diseaseEjection fractionHeart failureClinical outcomesHuman Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries
Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM, Velazquez EJ. Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. JACC Heart Failure 2015, 3: 579-590. PMID: 26251085, PMCID: PMC4530470, DOI: 10.1016/j.jchf.2015.05.003.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHeart failureMiddle-income countriesImmunodeficiency virusChronic diseasesBurden of HIVTraditional cardiovascular risk factorsCommon cardiac diagnosesCardiovascular risk factorsLarge observational studiesLife expectancySuccessful combination therapyCare of peopleAntiretroviral therapyClinical characteristicsTreatment patternsSociety guidelinesCombination therapyRisk factorsClinical studiesObservational studyDiagnostic criteriaCardiac diagnosisHigh mortalityCardiac glycosides
2013
The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results
Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ, Investigators S. The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results. JACC Heart Failure 2013, 1: 400-408. PMID: 24621972, PMCID: PMC3829618, DOI: 10.1016/j.jchf.2013.04.012.Peer-Reviewed Original ResearchConceptsMode of deathIschemic cardiomyopathy patientsMedical therapySTICH trialMyocardial infarction deathsCABG therapyCardiomyopathy patientsSudden deathProspective clinical trial dataAddition of CABGStrategy of CABGCoronary artery bypassReduced ejection fractionClinical events committeeClinical trial dataPre-specified definitionsCABG patientsArtery bypassCardiovascular deathNoncardiovascular deathEjection fractionHeart failureEvents committeeProtective effectCABGPrediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction
Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P, Køber L. Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction. Journal Of The American College Of Cardiology 2013, 61: 2365-2373. PMID: 23563128, DOI: 10.1016/j.jacc.2013.02.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedCause of DeathCohort StudiesConfidence IntervalsEchocardiography, DopplerFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrognosisProportional Hazards ModelsProspective StudiesRisk AssessmentSeverity of Illness IndexStroke VolumeSurvival RateVentricular Dysfunction, LeftConceptsGlobal longitudinal strainHeart failure hospitalizationVentricular ejection fractionAcute myocardial infarctionMyocardial infarctionFailure hospitalizationSecondary endpointsEjection fractionHigh-risk myocardial infarctionVentricular global longitudinal strainLeft ventricular ejection fractionLongitudinal strainHeart failure admissionsPrimary composite endpointCox regression analysisHigh-risk subjectsVentricular longitudinal strainImportant prognostic informationSignificant prognostic valueAssessment of GLSParticular clinical relevanceCardiovascular deathCause mortalityPrimary endpointCardiac death
2011
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction
Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European Journal Of Heart Failure 2011, 13: 148-153. PMID: 21037250, DOI: 10.1093/eurjhf/hfq194.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedCaptoprilCause of DeathConfidence IntervalsDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrognosisProportional Hazards ModelsRecurrenceRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftConceptsRecurrent myocardial infarctionFirst myocardial infarctionRisk of deathLeft ventricular dysfunctionMyocardial infarctionVentricular dysfunctionHeart failurePrognostic impactOne-year mortalityGlomerular filtration rateEarly reinfarctionLate reinfarctionTrial cohortUnstable anginaProlong survivalMedian timeMI survivorsFiltration ratePatientsContemporary managementContemporary treatmentInfarctionMortalityReinfarctionDeath
2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, Investigators F. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal 2010, 160: 145-151. PMID: 20598985, DOI: 10.1016/j.ahj.2010.02.037.Peer-Reviewed Original ResearchConceptsQ-wave myocardial infarctionMyocardial infarctionMyocardial ruptureClinical end-point committeeHigh-risk myocardial infarctionAcute Myocardial Infarction trialEnd-point committeeNonfatal cardiovascular eventsPresence of hemopericardiumQualifying MIMyocardial Infarction trialHigh-risk patientsGlomerular filtration ratePost-MI patientsAcute myocardial infarctionInferior myocardial infarctionDirect surgical visualizationKillip classCardiovascular eventsDiuretic useOral anticoagulantsVentricular dysfunctionClinical characteristicsFatal complicationHeart failure
2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2007
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal 2007, 155: 87-93. PMID: 18082495, DOI: 10.1016/j.ahj.2007.09.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmiodaroneCaptoprilCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProbabilityProportional Hazards ModelsReference ValuesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanVentricular DysfunctionConceptsVentricular systolic dysfunctionAmiodarone useAcute myocardial infarctionMyocardial infarctionSystolic dysfunctionLeft ventricular systolic dysfunctionPost-acute myocardial infarctionHazard ratio 1.5Higher Killip classTrials of amiodaroneKillip classVentricular dysfunctionBaseline characteristicsCardiovascular mortalityDiabetes mellitusHeart failureMedical regimenRandomized comparisonBaseline predictorsExcess mortalityCox modelSubsequent mortalityDay 1PatientsAmiodarone
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment